Eli Lilly 2Q profit jumps 16 pct on top drug sales

[July 22, 2010]  INDIANAPOLIS (AP) -- Eli Lilly says its second-quarter net income soared 16 percent, boosted in part by strong sales growth from the drugmaker's top-selling drugs.

The Indianapolis company says it earned $1.35 billion, or $1.22 per share, in the three months that ended June 30. That's up from $1.16 billion, or $1.06 per share, in the same period last year. Revenue rose 9 percent to $5.75 billion.

Excluding charges, net income was $1.24 per share.

Analyst polled by Thomson Reuters forecast earnings of $1.10 per share on $5.58 billion in revenue.

Sales for Lilly's best-selling drug, the antipsychotic Zyprexa, rose 5 percent, while revenue from its second-best seller, the antidepressant Cymbalta, climbed 17 percent.

[Associated Press]

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.